Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 31NIH 9OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Lymphoma, B-Cell, Marginal Zone 1Acute-Phase Reaction 1

Interventions

Metformin 2nilotinib 1Zinc Sulfate 1Zinc 1Vitamin D 1Simvastatin 1S Phase 1Ploidies 1Palliative Care 1Mannitol 1Magnetic Resonance Spectroscopy 1Hematologic Tests 1Granulocyte Colony-Stimulating Factor 1Genetic Testing 1Fatty Acids, Omega-3 1Docosahexaenoic Acids 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Cholecalciferol 1Calcium Carbonate 1Calcium 1Bortezomib 1Blood Transfusion 1Allopurinol 1ATP Citrate (pro-S)-Lyase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Bortezomib × Clear all
NCT05137860 2022-01-18

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Hospital General de Mexico

Phase 4 Unknown
56 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡